Stock Events

Pluri 

ILA2,075
1
+ILA0+0% Today

Statistics

Day High
2,120
Day Low
2,012
52W High
2,900
52W Low
1,776
Volume
895
Avg. Volume
5,389
Mkt Cap
160.46M
P/E Ratio
-
Dividend Yield
0%
Dividend
0.02

Upcoming

Dividends

0%Dividend Yield
10Y Growth
-8.04%
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

8MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.32
-0.21
-0.11
0
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PLUR.TA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture; and Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID-19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation; and a solution for the treatment of acute radiation syndrome through its collaboration in the United States with the National Institutes of Health and the U.S. Department of Defense. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Show more...
CEO
Mr. Yaacov Yanay
Employees
154
Country
Israel
ISIN
US72942G2030
WKN
000A3DQ8D

Listings